Clinical trial results:
ASpirin as a Treatment for ARDS (STAR) trial: a randomised, double-blind, allocation concealed, placebo-controlled phase 2 trial.

Summary

Results information

Trial information

Trial identification

Additional study identifiers

Sponsors

Paediatric regulatory details

Results analysis stage

General information about the trial

Population of trial subjects

Subjects enrolled per country

Subjects enrolled per age group

Subject disposition

Recruitment

Pre-assignment

Pre-assignment period milestones

Period 1

Arms

Arm title	

Arm title	

Number of subjects in period 1		

Baseline characteristics

Reporting groups	

Reporting group values			

End points

End points reporting groups

Primary: Oxygenation Index - Day 7

End point values				

Statistical analyses

Statistical analysis title	

Primary: Oxygenation index - Day 7 (Imputed)

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Oxygenation Index - Day 4

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Oxygenation index - Day 14	

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Respiratory Compliance - Day 4

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Respiratory Compliance - Day 7	

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Respiratory Compliance - Day 14	

End point values				

Statistical analyses

Secondary: Delta SOFA - Day 4	

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Delta SOFA - Day 7

End point values				

Statistical analyses

Statistical analysis title	

Secondary: Delta SOFA - Day 14

End point values				

Statistical analyses

Statistical analysis title	

Secondary: PF ratio - Day 4

End point values				

Statistical analyses

Statistical analysis title	

Secondary: PF ratio - Day 7	

End point values				

Statistical analyses

Statistical analysis title	

Secondary: PF ratio - Day 14

End point values				

Statistical analyses

Statistical analysis title	

Secondary: SUSAR

End point values				

Statistical analyses

Secondary: SOFA - Day 4

End point values	

Secondary: SOFA - day7

End point values				

Statistical analyses

Statistical analysis title	

Secondary: SOFA - day14	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Ventilator Free Day Score	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of ventilation - All patients	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of ventilation - Achieved unassisted breathing	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of ventilation - Died	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of ICU stay - All patients	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of ICU stay - Alive at discharge

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of ICU stay - Died

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of hospital stay - All patients	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of hospital stay - Alive at discharge	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: Duration of hospital stay - Died	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: All cause mortality - 28 day	

End point values				

Statistical analyses

Statistical analysis title	

Other pre-specified: All cause mortality - 90 day	

End point values				

Statistical analyses

Statistical analysis title	

Adverse events

Adverse events information	

Dictionary used	

Reporting groups	

Serious adverse events			

Non-serious adverse events			

More information

Substantial protocol amendments (globally)

Date	Amendment

Interruptions (globally)

Limitations and caveats